Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.

Published bySteffen Björn Baum Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and."— Presentation transcript:

1 Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, FFR, and angiographic assessments. Cohort B: 12-month OCT, FFR, and angiographic assessments. Cohort C: 12-month FFR and angiographic assessments. EES, everolimus-eluting stent; FFR, fractional flow reserve; FU, follow-up; ITT, intention-to-treat; OCT, optical coherence tomography. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, Volume 39, Issue 26, 21 June 2018, Pages 2460–2468, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, Volume 39, Issue 26, 21 June 2018, Pages 2460–2468, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 2 One-year Kaplan–Meier curves for target vessel failure (intention-to-treat population). CI, confidence ... Figure 2 One-year Kaplan–Meier curves for target vessel failure (intention-to-treat population). CI, confidence interval; EES, everolimus-eluting stent; HR, hazard ratio. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, Volume 39, Issue 26, 21 June 2018, Pages 2460–2468, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Take home figure Combo Stent Technology in HARMONEE
Take home figure Combo Stent Technology in HARMONEE. (A) Combo stent design: with abluminal bioabsorbable polymer-eluting ... Take home figure Combo Stent Technology in HARMONEE. (A) Combo stent design: with abluminal bioabsorbable polymer-eluting sirolimus and endoluminal anti-CD34+ antibody. (B) Anti-CD34+ antibody mechanism of action: attracting CD34+ endothelial progenitor cells to stent site that mature to functional endothelium. (C) HARMONEE mechanistic ‘healthy endothelium’ surrogate superiority: representative images index procedure (baseline) and 1-year angiographic results with Combo and everolimus-eluting stents that are quantitatively similar, but optical coherence tomography at 1 year shows more complete strut coverage and more homogeneous tissue with Combo than with everolimus-eluting stent. EPC, endothelial progenitor cell; FU, follow-up; OCT, optical coherence tomography. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, Volume 39, Issue 26, 21 June 2018, Pages 2460–2468, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and."

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.

Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Similar presentations

Ads by Google